ライフサイエンスコーパス: ursodeoxycholic acid

1 60% with inflammatory bowel disease, 46% on ursodeoxycholic acid).

2 ation of cholestasis, with weight-dosed oral ursodeoxycholic acid.

3 be attributable to liver transplantation or ursodeoxycholic acid.

4 maining 17% of bile acids were identified as ursodeoxycholic acid.

5 mplete response to first-line treatment with ursodeoxycholic acid.

6 re commonly in the 21 patients randomized to ursodeoxycholic acid.

7 ely to treatment with mitochondrially active ursodeoxycholic acid.

8 mic reticulum stress, which was countered by ursodeoxycholic acid.

9 recommended in favor of prophylactic use of ursodeoxycholic acid.

10 gitis may have never received treatment with ursodeoxycholic acid.

11 eceptor bile acid receptor agonists, and nor-ursodeoxycholic acid.

12 transformed 20 years ago with the advent of ursodeoxycholic acid.

13 intolerant to or inadequately responsive to ursodeoxycholic acid.

14 limit of normal (ULN) despite treatment with ursodeoxycholic acid.

15 r in patients with an inadequate response to ursodeoxycholic acid.

16 adequate response to first-line therapy with ursodeoxycholic acid.

17 c acid > cholic acid > hyodeoxycholic acid > ursodeoxycholic acid.

18 apidly triggered by a diet supplemented with ursodeoxycholic acid.

19 ry cirrhosis who had inadequate responses to ursodeoxycholic acid.

20 All patients were treated with ursodeoxycholic acid.

21 iet or control diet plus cholic acid (1%) or ursodeoxycholic acid (1%) for 10 days.

22 e, or incomplete response were randomized to ursodeoxycholic acid (13-15 mg/kg daily) or placebo for

23 lic acid (3alpha-OH, 7alpha-OH, 12alpha-OH), ursodeoxycholic acid (3alpha-OH, 7beta-OH), and lithocho

24 binations of gentamicin and chaperone drugs (ursodeoxycholic acid, 4-phenylbutyrate [4-PB]) were inve

25 colonic mucosal tissue in vitro In contrast, ursodeoxycholic acid (50-200 microM) inhibited both basa

26 Taurine-conjugated ursodeoxycholic acid, a hydrophilic bile acid, similarly

27 4-Phenyl butyric acid and taurine-conjugated ursodeoxycholic acid alleviated ER stress in cells and w

28 mittance and following treatment with either ursodeoxycholic acid alone (10 mg/kg thrice daily, n = 1

29 lus ursodeoxycholic acid was not superior to ursodeoxycholic acid alone for the prevention or occlusi

30 hemical response occurred under therapy with ursodeoxycholic acid, alone or in combination with immun

31 Of note, both ursocholanic acid and ursodeoxycholic acid also rescued mitochondrial function

32 acid, radioactivity was detected in both the ursodeoxycholic acid and chenodeoxycholic acid fractions

33 ntial forms of therapy, including the use of ursodeoxycholic acid and cholecystokinin.

34 alysis in 168 patients with PSC treated with ursodeoxycholic acid and followed up from November 2004

35 changes in the pharmacokinetic parameters of ursodeoxycholic acid and its conjugates.

36 tion of non-12alpha-hydroxylated bile acids, ursodeoxycholic acid and lithocholic acid.

37 activity calculation, and the routine use of ursodeoxycholic acid and low-dose steroids (modified pro

38 were similar before and after treatment with ursodeoxycholic acid and no different than after placebo

39 e drugs that antagonize BS toxicity, such as ursodeoxycholic acid and nor-ursodeoxycholic acid, may b

40 Ursodeoxycholic acid and S-adenosyl-L-methionine are the

41 Ursodeoxycholic acid and S-adenosylmethionine are anti-f

42 The combination of ursodeoxycholic acid and simvastatin for the resolution

43 on in serum alkaline phosphatase levels with ursodeoxycholic acid and the need to add second-line age

44 ients do not, however, respond adequately to ursodeoxycholic acid and therefore still remain at risk

45 might be reduced by early enteral feedings, ursodeoxycholic acid, and cholecystokinin-octapeptide.

46 its were corrected by oral administration of ursodeoxycholic acid, and the addition of an oral proton

47 compound ursolic acid and the licensed drug ursodeoxycholic acid are chemically closely related to u

48 results indicate that substantial amounts of ursodeoxycholic acid are formed in patients treated with

49 Corticosteroids or ursodeoxycholic acid are treatment options for patients

50 To evaluate the efficacy of ursodeoxycholic acid as adjunctive therapy in type 1 aut

51 acid as a naturally occurring compound, and ursodeoxycholic acid as an already licensed drug as prom

52 r, phenylbutyric acid and taurine-conjugated ursodeoxycholic acid attenuated HNE-induced leukocyte ro

53 Ursodiol (ursodeoxycholic acid) benefits patients with primary bil

54 mong patients with an inadequate response to ursodeoxycholic acid but may improve symptoms of pruritu

55 d by restoring biliary secretion with 24-nor-ursodeoxycholic acid but were significantly reduced by o

56 Use of ursodeoxycholic acid can improve alkaline phosphatase an

57 We conclude that ursodeoxycholic acid can improve certain laboratory test

58 Moreover, ursodeoxycholic acid can reduce apoptosis by minimizing

59 Ursodeoxycholic acid caused a dose-dependent decrease in

60 , sitosterol, cholic acid, deoxycholic acid, ursodeoxycholic acid, cholestyramine, bile fistula, lova

61 For ursodeoxycholic acid, clinical practice guidelines only

62 ith an incomplete response or intolerance to ursodeoxycholic acid, clinical trials have indicated tha

63 modifying BA synthesis or dietary intake of ursodeoxycholic acid could improve tumor immunotherapy i

64 In contrast, ursodeoxycholic acid did not exhibit any of these effect

65 Bile acids deoxycholic acid and ursodeoxycholic acid differentially regulate human beta-

66 Treatment with ursodeoxycholic acid does not reduce adverse perinatal o

67 The biguanide and ursodeoxycholic acid dual-modified multifunctional album

68 holic acid, the specific activity of biliary ursodeoxycholic acid exceeded the specific activity of c

69 nts with primary biliary cholangitis in whom ursodeoxycholic acid failed, based on a surrogate endpoi

70 Ursodeoxycholic acid (first-line therapy for most human

71 a multicenter randomized trial of high dose ursodeoxycholic acid for PSC.

72 Notably, 95% of patients were taking ursodeoxycholic acid for treatment of their primary bili

73 Maternal management is symptomatic with ursodeoxycholic acid; for the fetus, however, this is a

74 henodeoxycholic, deoxycholic, lithocholic or ursodeoxycholic acids, free and as their glycine or taur

75 e occurred in 74 (23%) of 322 infants in the ursodeoxycholic acid group and 85 (27%) of 318 infants i

76 serious adverse events were reported in the ursodeoxycholic acid group and six serious adverse event

77 is included 304 women and 322 infants in the ursodeoxycholic acid group, and 300 women and 318 infant

78 important, because effective treatment with ursodeoxycholic acid has been shown to halt disease prog

79 s a second-line therapy for patients failing ursodeoxycholic acid has improved outcomes for patients

80 Ursodeoxycholic acid has the potency to suppress eosinop

81 ining factor in the pathogenesis of PBC with ursodeoxycholic acid helping to restore this protective

82 biliary cholangitis who are unresponsive to ursodeoxycholic acid; however, approximately 50% of pati

83 was confirmed for both ursocholanic acid and ursodeoxycholic acid in a Parkin-deficient neuronal mode

84 Treatment should be offered with oral ursodeoxycholic acid in a total daily dose of 10-15 mg/k

85 Initial results from high-dose ursodeoxycholic acid in halting disease progression, how

86 While post-LT use of ursodeoxycholic acid in PBC is clearly beneficial, no ef

87 periority of 24-norursodeoxycholic acid over ursodeoxycholic acid in reducing histological disease pr

88 However, ursodeoxycholic acid increased activity 84% (P < .05) an

89 Ursodeoxycholic acid inhibits uptake and vasoconstrictor

90 o not respond sufficiently, or patients with ursodeoxycholic acid intolerance, conditionally licensed

91 Ursodeoxycholic acid is a readily available and generall

92 experiments provide the first evidence that ursodeoxycholic acid is effective for preventing adenoma

93 Ursodeoxycholic acid is the preferred first-line therapy

94 Ursodeoxycholic acid is widely used as a treatment witho

95 However, ursodeoxycholic acid is widely used since it improves th

96 Ursodeoxycholic acid may have a role as a colorectal and

97 Oral administration of ursodeoxycholic acid may improve bile flow and reduce ga

98 of multiple cholesterol stone formation, and ursodeoxycholic acid may partially halt the formation of

99 xicity, such as ursodeoxycholic acid and nor-ursodeoxycholic acid, may be effective at all disease st

100 c acid or who have an inadequate response to ursodeoxycholic acid monotherapy.

101 s having disease that was well-controlled on ursodeoxycholic acid monotherapy.

102 e enrolled and randomly allocated to receive ursodeoxycholic acid (n=305) or placebo (n=300).

103 The chemoprevention effects of ursodeoxycholic acid on colorectal dysplasia await furth

104 ng the effects of deoxycholic acid (DCA) and ursodeoxycholic acid on the expression and release of Hb

105 Participants were randomly assigned 1:1 to ursodeoxycholic acid or placebo, given as two oral table

106 ) occurred as commonly in patients receiving ursodeoxycholic acid or placebo.

107 recommended for patients who cannot tolerate ursodeoxycholic acid or who have an inadequate response

108 id (deoxycholic acid, chenodeoxycholic acid, ursodeoxycholic acid, or glycochenodeoxycholic acid) in

109 he concentrations of the secondary bile acid ursodeoxycholic acid (p = 0.033) and the plant sterol si

110 s with inadequate response or intolerance to ursodeoxycholic acid, peroxisome proliferator-activated

111 Despite therapy with ursodeoxycholic acid, prednisone, and then tacrolimus, h

112 Ursodeoxycholic acid prevents eosinophilic degranulation

113 injury by enhancing Cyp2b10 expression, and ursodeoxycholic acid provided partial improvement.

114 In addition, the FXR antagonist ursodeoxycholic acid reduced the proliferation of human

115 We aimed to evaluate whether ursodeoxycholic acid reduces adverse perinatal outcomes

116 Ursodeoxycholic acid remains the most studied medical tr

117 = 0.02). A sensitivity analysis that defined ursodeoxycholic acid response as normalization of alkali

118 C, which is unrelated to disease severity or ursodeoxycholic acid response, is significant and comple

119 Here we show that polymerized ursodeoxycholic acid, selected from a panel of bile-acid

120 el insights into the mechanisms of action of ursodeoxycholic acid should advance our understanding of

121 ears following biopsy, including response to ursodeoxycholic acid, show identical changes to patients

122 Additional treatment with 4-PB and ursodeoxycholic acid significantly increased the canalic

123 ies, showed identical treatment responses to ursodeoxycholic acid, similar rates and types of nonhepa

124 Ursodeoxycholic acid strongly promoted interleukin (IL)-

125 ewed interest in developing therapies beyond ursodeoxycholic acid that are aimed at both slowing dise

126 The formation of ursodeoxycholic acid, the 7 beta-hydroxy epimer of cheno

127 bile acid--binding resins and the choleretic ursodeoxycholic acid, the medical management of cholesta

128 Ursodeoxycholic acid, the standard first-line treatment

129 dults with PBC and an inadequate response to ursodeoxycholic acid therapy (i.e., alkaline phosphatase

130 The precise role of weight reduction and ursodeoxycholic acid therapy in the favorable alteration

131 cirrhosis who had an inadequate response to ursodeoxycholic acid therapy.

132 Patients maintained their existing dose of ursodeoxycholic acid throughout the study.

133 esponse to or unacceptable side effects with ursodeoxycholic acid to receive once-daily elafibranor,

134 ative reductions in ALP were similar between ursodeoxycholic acid-treated and untreated patients.

135 Ursodeoxycholic acid-treated DCs have less capacity than

136 Ursodeoxycholic acid treatment of OVA-sensitized mice pr

137 18:0/18:1), PS(14:1/14:0), dihydroxyacetone, ursodeoxycholic acid, tryptophan, L-valine, cycloserine,

138 assigned to ceftriaxone also received 300 mg ursodeoxycholic acid twice daily and those assigned to p

139 Ursodeoxycholic acid (UDC) and hyocholic acid (HC) feedi

140 d, double-blind, placebo-controlled trial of ursodeoxycholic acid (UDCA) (10-12 mg/kg/d) taken as a s

141 In the overall cohort, the use of ursodeoxycholic acid (UDCA) (odds ratio [OR], 0.36 [95%

142 Intriguingly, treatment with ursodeoxycholic acid (UDCA) ameliorates eosinophilia as

143 Oral administration of ursodeoxycholic acid (UDCA) and cholesterol causes bile

144 uate the safety and estimate the efficacy of ursodeoxycholic acid (UDCA) and clofibrate in the treatm

145 We identified ursodeoxycholic acid (UDCA) and deoxycholic acid (DCA) a

146 Ursodeoxycholic acid (UDCA) and histone deacetylase 6 in

147 Bile acids, mainly ursodeoxycholic acid (UDCA) and its conjugated species g

148 ated the potential of therapeutic bile acids ursodeoxycholic acid (UDCA) and obeticholic acid (OCA, 6

149 patients with AMA-negative PBC treated with ursodeoxycholic acid (UDCA) and/or liver transplantation

150 igation (BDL) in mice and how treatment with ursodeoxycholic acid (UDCA) and/or S-adenosylmethionine

151 olic acid (DCA), lithocholic acid (LCA), and ursodeoxycholic acid (UDCA) are implicated in the pathog

152 tients with PBC do not adequately respond to Ursodeoxycholic acid (UDCA) as a first-line treatment, p

153 iary cholangitis (PBC) patients treated with ursodeoxycholic acid (UDCA) at month 12 and at last chec

154 Ursodeoxycholic acid (UDCA) can protect hepatocytes from

155 acid (DCA), chenodeoxycholic acid (CDCA) or ursodeoxycholic acid (UDCA) caused sustained MAPK activa

156 evels of short-chain fatty acids (SCFAs) and ursodeoxycholic acid (UDCA) compared to V-HCC.

157 The novel rosuvastatin (RO) and ursodeoxycholic acid (UDCA) conjugate (ROUA) is designed

158 s are inconclusive regarding the efficacy of ursodeoxycholic acid (UDCA) for treating primary scleros

159 Ursodeoxycholic acid (UDCA) has been shown in small, ope

160 Ursodeoxycholic acid (UDCA) has been shown to be a safe

161 Ursodeoxycholic acid (UDCA) has been suggested to be of

162 Ursodeoxycholic acid (UDCA) has previously been shown to

163 Ursodeoxycholic acid (UDCA) has shown effectiveness as a

164 Ursodeoxycholic acid (UDCA) improves liver function in p

165 d-line treatment for PBC in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate

166 Ursodeoxycholic acid (UDCA) increased total plasma BA le

167 more, we investigated the mechanism by which ursodeoxycholic acid (UDCA) inhibits LXR-induced lipogen

168 Ursodeoxycholic acid (UDCA) is a beneficial medical ther

169 Whereas ursodeoxycholic acid (UDCA) is a commonly used treatment

170 Ursodeoxycholic acid (UDCA) is a safe and effective medi

171 Ursodeoxycholic acid (UDCA) is a safe and effective medi

172 Ursodeoxycholic acid (UDCA) is a safe and effective trea

173 Ursodeoxycholic acid (UDCA) is a synthetic bile acid cap

174 Ursodeoxycholic acid (UDCA) is no longer recommended for

175 nt of primary biliary cholangitis (PBC) with ursodeoxycholic acid (UDCA) is not always sufficient to

176 Ursodeoxycholic acid (UDCA) is one of the first-line the

177 Ursodeoxycholic acid (UDCA) is the only approved treatme

178 Ursodeoxycholic acid (UDCA) is the only approved treatme

179 Despite limited benefits, ursodeoxycholic acid (UDCA) is the only Food and Drug Ad

180 Ursodeoxycholic acid (UDCA) is the only known beneficial

181 Ursodeoxycholic acid (UDCA) is used for the treatment of

182 Ursodeoxycholic acid (UDCA) is used to treat primary bil

183 Ursodeoxycholic acid (UDCA) is widely used for cholangio

184 Standard doses of ursodeoxycholic acid (UDCA) lead to improvements in bioc

185 This study sought to assess the effects of ursodeoxycholic acid (UDCA) on endothelial function and

186 d a meta-analysis to evaluate the effects of ursodeoxycholic acid (UDCA) on pruritus, liver test resu

187 Ursodeoxycholic acid (UDCA) or S-adenosylmethionine (SAM

188 We have also shown that ursodeoxycholic acid (UDCA) prevented AOM-induced colon

189 Ursodeoxycholic acid (UDCA) prevents the formation of ga

190 The hydrophilic bile salt ursodeoxycholic acid (UDCA) protects against the membran

191 Ursodeoxycholic acid (UDCA) protects cells from the apop

192 Although ursodeoxycholic acid (UDCA) remains the first-line treat

193 Complete biochemical response to ursodeoxycholic acid (UDCA) therapy in early patients wi

194 rmine the influence of IBD and the effect of ursodeoxycholic acid (UDCA) therapy on the course of the

195 aimed at investigating the effect of adding Ursodeoxycholic acid (UDCA) to CBD stenting alone in ord

196 Here we report salvage therapy with ursodeoxycholic acid (UDCA) to prevent rCDI in 16 high-r

197 ed that feeding the cytoprotective bile acid ursodeoxycholic acid (UDCA) to rats resulted in signific

198 ound z-guggulsterone and the off-patent drug ursodeoxycholic acid (UDCA) to reduce FXR signalling and

199 Ursodeoxycholic acid (UDCA) treatment can reduce itch an

200 High-dose (28-30 mg/kg/day) ursodeoxycholic acid (UDCA) treatment improves serum liv

201 ated risk factors, and the use and effect of ursodeoxycholic acid (UDCA) treatment.

202 GF mdr2(-/-) mice and abrogated in vitro by ursodeoxycholic acid (UDCA) treatment.

203 We model the effect of ursodeoxycholic acid (UDCA) upon levels of angiotensin-c

204 d, double-blind, placebo-controlled trial of ursodeoxycholic acid (UDCA) versus placebo.

205 ), and effects of treatment with 4-PB and/or ursodeoxycholic acid (UDCA) were assessed.

206 ium bolteae, which promoted the formation of ursodeoxycholic acid (UDCA), a precursor of GUDCA.

207 Treatment includes ursodeoxycholic acid (UDCA), but it is not clear if UDCA

208 e of them were treated in the follow up with ursodeoxycholic acid (UDCA), eight received during a tri

209 hypertransaminasemia (ADAH), its response to ursodeoxycholic acid (UDCA), elucidate its pathophysiolo

210 efficacy criteria determined the response to ursodeoxycholic acid (UDCA), fibrates (n=93), and OCA (n

211 se and the first line available treatment is ursodeoxycholic acid (UDCA), however, direct and indirec

212 diagnosis reports, response to therapy with ursodeoxycholic acid (UDCA), laboratory results, and sym

213 Ursodeoxycholic acid (UDCA), methotrexate, and colchicin

214 frequently progresses despite treatment with ursodeoxycholic acid (UDCA), the only approved therapy.

215 eutic option available for these patients is ursodeoxycholic acid (UDCA), which slows the progression

216 The biochemical response to ursodeoxycholic acid (UDCA)--so-called "treatment respon

217 alkaline phosphatase levels in this largely ursodeoxycholic acid (UDCA)-responding, early-disease st

218 Normal alkaline phosphatase (ALP) levels in ursodeoxycholic acid (UDCA)-treated patients with primar

219 d in AC and was prevented by the hydrophilic ursodeoxycholic acid (UDCA).

220 SC) receive oral vancomycin therapy (OVT) or ursodeoxycholic acid (UDCA).

221 with PBC and PSC biochemically responded to Ursodeoxycholic Acid (UDCA).

222 in nonresponders to first-line therapy with ursodeoxycholic acid (UDCA).

223 nthesis and steady-state pharmacokinetics of ursodeoxycholic acid (UDCA).

224 ntional treatment with the natural bile acid ursodeoxycholic acid (UDCA).

225 stasis of pregnancy (ICP) and treatment with ursodeoxycholic acid (UDCA).

226 nged substantially with the introduoction of ursodeoxycholic acid (UDCA).

227 irrhosis (PBC) and an incomplete response to ursodeoxycholic acid (UDCA).

228 Administration of the secondary bile acid ursodeoxycholic acid (UDCA; ursodiol) inhibits the life

229 ecifically, our approach involves the use of ursodeoxycholic acid (Urso) due to its ability to decrea

230 Sulindac was tested in combination with ursodeoxycholic acid (ursodiol), a naturally occurring 7

231 deoxycholate, an ionic salt of berberine and ursodeoxycholic acid), versus placebo that was conducted

232 ar 50 mg/day, or seladelpar 200 mg/day while ursodeoxycholic acid was continued.

233 f 1 kg), and the finding that ofloxacin plus ursodeoxycholic acid was not superior to ursodeoxycholic

234 The ursodeoxycholic acid was synthesized from chenodeoxychol

235 Treatment responses to corticosteroids or ursodeoxycholic acid were poor.

236 ith inadequate response to or intolerance to ursodeoxycholic acid were randomised to receive placebo,

237 NF-kappaB, an effect that was attenuated by ursodeoxycholic acid, whereas an NF-kappaB inhibitor, BM

238 , the foundational treatment of PBC has been ursodeoxycholic acid, which delays disease progression i

239 Ursodeoxycholic acid, which in vivo is converted to its

240 Moreover, the hepatoprotective bile acid ursodeoxycholic acid, which reverses hydrophobic bile ac

241 ed drug in primary sclerosing cholangitis is ursodeoxycholic acid, which, despite a range of potentia

242 gitis and intolerance/inadequate response to ursodeoxycholic acid who initiated OCA therapy were comp

243 olled trials evaluating PPAR agonists versus ursodeoxycholic acid, with or without placebo.

244 properties of hydrophilic bile acids such as ursodeoxycholic acid, with the distinct ability to speci